Value-Added Specialist Hyloris Launches IPO
Proceeds Will Allow Firm To Focus On US 505(b)(2) Opportunities
Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.
